According to a recent study, U.S. veterans are more likely to have a history of skin cancer, melanoma, and psoriasis when compared to non-veterans.
Extended guselkumab dosing effective for PsO super responders
According to a recent study, extending the dosing interval of guselkumab from eight weeks to sixteen weeks is non-inferior for treating moderate-to-severe psoriasis in super-responders.
PsO disease severity linked to missed work days
According to a recent study, patients with moderate-to-severe psoriasis are more than twice as likely to take a half-day off work than those with mild psoriasis.
Study suggests significant autoimmune disease prevalence in PsO patients
According to a recent study, there is a significant autoimmune disease prevalence in psoriasis patients.
Tildrakizumab efficacious in treating scalp psoriasis
According to a recent study, tildrakizumab was shown to be efficacious in treating moderate-to-severe plaque psoriasis on the scalp.
Topical treatment improves sleep quality in PsO, AD patients
According to a recent study, topical treatment decreases itch and improves sleep patterns in patients with psoriasis and atopic dermatitis.
Study finds link between skin disorder visibility and stigma
According to a recent study, the visibility of a skin disorder is directly linked to stigma including bullying.
Topical melatonin, rosuvastatin may reduce severity of mild-to-moderate plaque PsO
According to a recent study, topical melatonin and topical rosuvastatin were both effective in reducing the severity of mild-to-moderate plaque psoriasis.
Guselkumab efficacious in PsO patients with history of cancer
According to a recent study, guselkumab is efficacious in patients with moderate-to-severe psoriasis and a history of cancer.
Study shows apremilast effective for moderate-to-severe plaque PsO in pediatric patients
According to a recent study, apremilast is effective for the treatment moderate-to-severe plaque psoriasis short-term in pediatric patients.
HealthMinute.TV 